Date: 2017-09-13
Type of information: Nomination
Compound: pre-clinical director
Company: Eyevensys (France)
Therapeutic area: Rare diseases - Genetic diseases - Ophtalmological diseases
Type agreement: nomination
Action mechanism:
Disease:
Details:
- • On September 13, 2017, Eyevensys announced the appointment of Thierry Bordet, Ph.D. as Pre-Clinical Director. Thierry Bordet will be directing Eyevensys’ pre-clinical development efforts, including the generation of potential clinical candidates for the range of eye diseases that the company is targeting such as retinal vein occlusion and retinitis pigmentosa. He will also oversee Eyevensys’ relationships with potential academic and industrial partners.
- Thierry brings more than 15 years’ experience in the biotechnological sector having managed drug development programs for small molecules, gene therapies, cell-based therapies and tissue engineered products. He was most recently Pre-Clinical Development Director at the Biotherapies Institute for Rare Diseases, in Evry, France where he designed development strategies for advanced therapy medicinal products for various indications, including inherited retinitis pigmentosa. Prior to that he spent 12 years at Trophos managing the company’s drug screening and early development programs for neurodegenerative indications. Thierry has a Ph.D. in microbiology and virology from Pierre & Marie Curie University PARIS VI.
Financial terms:
Latest news:
Is general: Yes
